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Acute myeloid leukemia (AML) is the most commonly diagnosed cancer affecting the myeloid lineage of hematopoiesis in adults. Although standard chemotherapy for AML treatment initially leads to complete remission (CR) in 60-80% of patients, 50-70% of patients relapse after CR in the first 3 years. 1 Therefore, the search for new treatment strategies to eliminate minimal residual disease has encouraged targeted immunotherapeutic approaches. A promising target is the 67 kDa transmembrane cell surface glycoprotein CD33, which is a common and widespread marker for acute leukemias arising from the myeloid lineage. 2 In addition, it is also assumed to be expressed on leukemic stem and progenitor cells. 3, 4 Targeting CD33 thus might be attractive for the treatment of AML patients where CR cannot be achieved after initial standard chemotherapy, but also for patients with minimal residual disease after first cytomorphologic remission of the disease. Therefore, a series of anti-CD33-based therapeutic concepts were followed over the past decades including the retargeting of T cells with bispecific antibodies (bsAbs). 5, 6 Conflicting data concerning cross-reactivity of anti-CD33 Abs with human stem cell progenitors (HSCPs) are reported in the literature, 5, 7 raising the question whether or not hematopoiesis will be suppressed after a CD33-specific retargeting of cytotoxic effector T cells. Based on novel murine anti-CD33 and anti-CD3 monoclonal antibodies (mAbs), we recently established a novel bsAb for retargeting of T cells to AML blasts. 8, 9 In light of a future clinical application, we have now humanized this bsAb construct to reduce the risk of human anti-mouse antibody responses and optimized its cytotoxic potential against AML blasts. The resulting fully humanized bsAb CD33-CD3 is capable of efficiently redirecting T cells to AML blasts in picomolar concentrations and does not impair the multilineage reconstitution potential of HSCPs.
For humanization, the CDR regions of both Ab-binding domains of the previously described anti-CD3 and anti-CD33 mAbs were in silico engrafted to the best fitting human framework regions. 9, 10 Subsequently, the variable light and heavy chains were synthesized and arranged in tandem format by using glycineserine linkers as connecting elements. [8] [9] [10] To evaluate functional efficacy of the novel humanized bsAb CD33-CD3, both chromium release and flow cytometry-based assays were performed as described previously. [9] [10] [11] Freshly isolated human pan T cells served as effector cells in all in vitro and in vivo assays (Figure 1 ). By performing a flow cytometry-based assay using decreasing Ab concentrations, we could show that the bsAb efficiently redirects T cells to eradicate CD33 þ AML cells even at picomolar concentrations ( Figure 1a , n ¼ 4). In addition, killing properties of bsAbredirected T cells were examined by performing chromium release assays against various AML cell lines. As shown in Figure 1b Accepted article preview online 17 January 2013; advance online publication, 8 February 2013 Letters to the Editor (n ¼ 3), efficient lysis of different CD33 þ AML cell lines was achieved in the presence of the bsAb CD33-CD3, whereas no significant lysis of target cells occurred in the absence of any Ab or in the presence of a humanized control bsAb sharing the same anti-CD3 domain as the bsAb CD33-CD3. Interestingly, tumor cell elimination was independent from antigen density on target cells. This is an important feature of the T cell engaging bsAb as AML blasts, show varying CD33 expression levels. Most importantly, bsAb-redirected T cells were further able to mediate an efficient lysis of patient-derived AML blasts at low effector-to-target (e:t) ratios. Representative data of one donor are depicted in Figure 1c . Finally, we studied the ability of the crosslinking bsAb CD33-CD3 to mediate an antitumor response in immunodeficient NOD/SCID IL2Rg À / À mice. In a first experiment, the CD33 þ AML cell line MOLM-13 and T cells were incubated with or without the bsAb CD33-CD3 or humanized control bsAb for 6 h prior to retrobulbar injection into mice. As shown in Figures 1d, 2.5 weeks after setup of the experiment, the majority of mice in control groups developed tumors at the injection side (Figure 1d, left panel) . Interestingly, eye tumors were not visible in mice treated with the bsAb. The macroscopically visible differences in the development of eye tumors were mirrored by the observed bone marrow (BM) chimerism (Figure 1d, right panel) . Injection of tumor and T cells together with the bsAb CD33-CD3 resulted in a significantly lower BM chimerism (percentage of human CD45 þ CD33 þ cells) compared to that group in which tumor and effector cells were injected alone. In a second in vivo experiment, it was further proven that bsAb-redirected T cells are able to inhibit the outgrowth of established tumors. For this purpose, MOLM-13 AML blasts were injected into immunodeficient mice prior to treatment. Administration of freshly isolated T cells with or , see table in B) . Thereafter, one part of the cells was analyzed for relative numbers of CD3 þ and CD33 þ cells as well as for the presence of the activation markers CD69 and CD25 on bsAb-redirected CD3 þ -T cells as shown for those conditions where T cells were present in one of the representative donor (a). In addition, another part of the samples was seeded in methylcellulosebased medium and CFU-G, CFU-GM, CFU-M, CFU-GEMM and BFU-E were counted after 10 days as recently described 14 (b) . Note that CFUGEMMs were not observed in any case and therefore this group was omitted from the figure. The major part of the samples was injected into three sublethally irradiated NOD/SCID IL2Rg À / À mice/group (three donors) or four mice/group (one donor) and pB chimerism was monitored over 20 weeks (c). After 20 weeks, mice were sacrificed and BM was analyzed for the presence of human hematopoietic cells on a BD LSRII flow cytometer (d). Human T cell chimerism (hCD45 þ CD3 þ ) was below 1% in all experiments, human B-cell chimerism (hCD45 þ CD19 þ ) varied between 1-25%. Effector T cells were irradiated with 8 Gy before setup of the experiment to prevent xenograft reactivity in host mice. Irradiated T cells were tested beforehand to exhibit similar killing abilities as non-irradiated T cells upon crosslinking with the bsAb CD33-CD3 (data not shown). Pooled results of four independently analyzed healthy donors are shown in (b, c and d).
without the bsAb CD33-CD3 or control bsAb was started the following day and repeated on days 3 and 5. Two weeks later, mice were sacrificed and percentage of human CD33 þ cells in the BM was determined. In mice treated with T cells and the bsAb CD33-CD3, only a low percentage of human CD33 þ cells could be detected, whereas BM of control groups contained up to 90% human CD33 þ AML cells (Figure 1e) .
Having established the fully humanized bsAb CD33-CD3, we asked the question, whether or not human CD34 þ HSCPs are affected by bsAb-redirected T cells. For that purpose, freshly isolated human T cells were incubated with isolated autologous CD34 þ HSCPs in the presence or absence of the bsAb CD33-CD3 for 20 h. Thereafter, the hematopoietic potential of HSCPs was analyzed. As shown for one representative donor, T cells were activated in the presence of the bsAb CD33-CD3 as demonstrated by the upregulation of the activation markers CD69 and CD25 (Figure 2a) . However, in vitro analysis of the hematopoietic potential of bsAb-treated HSCPs in colony forming unit (CFU) assays did not reveal any differences to control groups (Figure 2b, n ¼ 4) . Furthermore, HSCPs incubated with bsAbredirected T cells were injected into sublethally irradiated NOD/ SCID IL2Rg À / À mice and development of chimerism was monitored in the peripheral blood (pB) over 20 weeks. No significant differences in the development of total and myeloid chimerism in the pB could be observed between treated and control groups (Figure 2c ). After 20 weeks, mice were sacrificed and BM chimerism was analyzed. In line with pB chimerism, no differences could be detected for total or myeloid chimerism in treated versus control groups (Figure 2d ). In addition, chimerism for CD34 þ stem cells as well as B-and T cell compartments was analyzed without any detectable differences between the groups (data not shown).
Taken together, the novel fully humanized bsAb CD33 À CD3 is capable of redirecting human T cells efficiently toward CD33 þ AML blasts as demonstrated by lysis of both AML cell lines and patient-derived blasts. According to our data, effective tumor cell killing requires only picomolar Ab concentrations, and is independent of antigen density on target cells. As an important point for a clinical application of this bsAb, our data provide evidence that although T cells are activated against autologous HSCPs in the presence of the bsAb CD33 À CD3, the hematopoietic potential of the HSCPs is not affected by redirected T cells. This is in line with recent reports that T cells engrafted with a CD33-specific chimeric antigen receptor exhibit cytotoxic effects against autologous CD33 þ hematopoietic precursor cells, but do not severely impair the function of HSCPs. 12 Moreover, in clinical studies, a multilineage engraftment of CD33-depleted autografts in AML patients was observed. 13 As a consequence, despite destroying healthy cells of the myeloid compartment during treatment with bsAb-redirected T cells as also recently demonstrated by other groups, 6 the HSCP pool itself is most likely not harmed and can replenish the myeloid cell lineage after stopping the treatment. In our opinion, this study represents an important step to further path the way toward a clinical application of this promising therapeutic strategy.
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